初始部分缓解后再次挑战[177Lu]Lu-PSMA-617放射配体治疗在转移性去势抵抗性前列腺癌患者中的疗效与安全性:前瞻性注册研究(REALITY研究)评估
基于前瞻性注册研究REALITY(NCT04833517),47例对初始[177Lu]Lu-PSMA-617放射配体治疗有生化反应后进展的转移性去势抵抗性前列腺癌患者接受至少1个(最多3个)疗程的再次挑战治疗。再次挑战后27/47例(57.4%)实现PSA下降至少50%,中位无进展生存期8.7个月,中位总生存期22.7个月,未观察到CTCAE分级不良事件严重恶化。
要点
- 再次挑战[177Lu]Lu-PSMA-617后57.4%(27/47)患者PSA下降≥50%。
- 全部患者中位PFS 8.7个月,中位OS 22.7个月,均自首次再次挑战疗程起算。
- 再次挑战应答者中位OS 27.3个月,未观察到CTCAE不良事件严重恶化。
核心结论
- [177Lu]Lu-PSMA-617再次挑战与显著的PSA反应、令人鼓舞的生存结局及非常良好的安全性相关,作者认为应被视为既往从PSMA-RLT获益的mCRPC患者的一种直接治疗选择。
研究设计与样本
- 前瞻性注册研究(REALITY研究,NCT04833517)纳入47例对初始[177Lu]Lu-PSMA-617 RLT有生化反应后出现疾病进展的mCRPC患者,接受至少1个(最多3个)疗程的再次挑战治疗。
主要发现
- 一个疗程再次挑战后,27/47例(57.4%)实现PSA下降至少50%。
- 全部患者中位PFS为8.7个月,中位OS为22.7个月,均自首次再次挑战疗程给药起算。
- 再次挑战应答者(PSA下降>50%)中位OS为27.3个月。
- 这些患者中,初始与再次挑战RLT的PFS之间发现显著相关性(r=0.4128,p=0.0323)。
- 10例接受第二个疗程、3例接受第三个疗程再次挑战,分别有8/10和3/3例对重复RLT再次挑战有反应;未观察到CTCAE标准评估的不良事件严重恶化。
临床怎么用
- 作者认为,[177Lu]Lu-PSMA-617再次挑战应被视为既往从PSMA-RLT获益的mCRPC患者的一种直接治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Rechallenge of [177Lu]Lu-PSMA-617 radioligand therapy (RLT) was proposed for patients who initially responded to PSMA-RLT experiencing partial remission, but relapsed into progression after a certain period of remission. However, only limited data is available regarding this approach. In this study, we analyzed the efficacy and safety profile of one or more series of [177Lu]Lu-PSMA-617 RLT rechallenge in patients from a prospective registry (REALITY Study, NCT04833517) after they initially benefited from PSMA-RLT. METHODS: Forty-seven patients with metastatic castration-resistant prostate cancer (mCRPC) who had biochemical response to initial [177Lu]Lu-PSMA-617 RLT followed by disease progression received at least one (up to three) series of [177Lu]Lu-PSMA-617 RLT rechallenge. Biochemical response rates based on prostate-specific antigen (PSA) serum value, PSA-based progression-free survival (PFS) and overall survival (OS) were calculated. Adverse events of the treatment were assessed according to 'common terminology criteria for adverse events' (CTCAE). RESULTS: After one series of RLT rechallenge, a PSA decline of at least 50% was achieved in 27/47 patients (57.4%). The median PFS of all patients was 8.7 mo and the median OS was 22.7 mo, each calculated from the administration of the first rechallenge series. Patients who responded (PSA decline > 50%) to the rechallenge showed a median OS of 27.3 mo. Regarding PFS, a significant correlation (r = 0.4128, p = 0.0323) was found for these patients comparing initial and rechallenge RLT. Ten patients received a second and 3 patients received a third rechallenge series with 8/10 and 3/3 patients responding to repeated RLT rechallenge. No severe deterioration of adverse events rated by CTCAE criteria was observed. CONCLUSION: [177Lu]Lu-PSMA-617 RLT rechallenge is associated with significant PSA response and encouraging survival outcome as well as a very favourable safety profile and should therefore be considered as a straight-forward treatment option in mCRPC patients, who previously benefited from PSMA-RLT.
引用
- Rosar F, Schuler J, Burgard C, et al. Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study). Eur J Nucl Med Mol Imaging. 2024. PMID: 39008067. doi:10.1007/s00259-024-06825-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。